Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

(2021) Stephen J. Nicholls et al.   Cardiovascular Diabetology

SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities

(2021) Rochelle P. Walensky et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection

(2021) Richard J. Mills et al.   CELL

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

(2020) Renhong Yan et al.   SCIENCE

The Stanford Hall consensus statement for post-COVID-19 rehabilitation

(2020) Robert M Barker-Davies et al.   BRITISH JOURNAL OF SPORTS MEDICINE

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

(2020) Vanessa Monteil et al.   CELL

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

(2020) Mehmet Soy et al.   CLINICAL RHEUMATOLOGY

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes

(2020) Kausik K. Ray et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

(2020) Yijin Wang et al.   JOURNAL OF HEPATOLOGY

SARS-CoV-2 and viral sepsis: observations and hypotheses

(2020) Hui Li et al.   LANCET

Epidemiology of COVID-19 Among Children in China

(2020) Yuanyuan Dong et al.   PEDIATRICS

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation

(2020) Omer Gilan et al.   SCIENCE

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

(2020) Sebastiano Bruno Solerte et al.   ACTA DIABETOLOGICA

Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease

(2020) Sylwia Wasiak et al.   Cardiovascular Therapeutics

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

(2020) Wafaa B. Alsoussi et al.   JOURNAL OF IMMUNOLOGY

Extrapulmonary complications of COVID‐19: A multisystem disease?

(2020) Kenneth I. Zheng et al.   JOURNAL OF MEDICAL VIROLOGY

The protein expression profile of ACE2 in human tissues

(2020) Feria Hikmet et al.   Molecular Systems Biology

Management of post-acute covid-19 in primary care

(2020) Trisha Greenhalgh et al.   BMJ-British Medical Journal

The COVID-19 Cytokine Storm; What We Know So Far

(2020) Dina Ragab et al.   Frontiers in Immunology

The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike

(2020) Yu Li et al.   iScience

Long-term Health Consequences of COVID-19

(2020) Carlos del Rio et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

(2020) M. Alejandra Tortorici et al.   SCIENCE

Covid-19: Remdesivir has little or no impact on survival, WHO trial shows

(2020) Owen Dyer   BMJ-British Medical Journal

Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator

(2020) Jingwei Bian et al.   Acta Pharmaceutica Sinica B

Airborne Transmission of COVID-19: Aerosol Dispersion, Lung Deposition, and Virus-Receptor Interactions

(2020) Yi Y. Zuo et al.   ACS Nano

Cytokine Storm

(2020) David C. Fajgenbaum et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2

(2020) Yuanyuan Qiao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism

(2019) Laura M. Tsujikawa et al.   Clinical Epigenetics

BET Bromodomain Inhibitor iBET151 Impedes Human ILC2 Activation and Prevents Experimental Allergic Lung Inflammation

(2019) Bernhard Kerscher et al.   Frontiers in Immunology

Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease

(2019) Mathias Haarhaus et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease

(2018) Ewelina Kulikowski et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Apabetalone downregulates factors and pathways associated with vascular calcification

(2018) Dean Gilham et al.   ATHEROSCLEROSIS

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)

(2017) Sylwia Wasiak et al.   Journal of Cardiovascular Translational Research

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease

(2016) Dean Gilham et al.   ATHEROSCLEROSIS

Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system

(2016) C. Klemann et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

(2015) Michael Zengerle et al.   ACS Chemical Biology

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial

(2015) Stephen J. Nicholls et al.   American Journal of Cardiovascular Drugs

A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice

(2014) Ravi Jahagirdar et al.   ATHEROSCLEROSIS

Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression

(2014) Mar Gacias et al.   CHEMISTRY & BIOLOGY

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist

(2014) Kevin G. McLure et al.   PLoS One

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain

(2013) S. Picaud et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family

(2012) Panagis Filippakopoulos et al.   CELL

Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry

(2012) M. Kawase et al.   JOURNAL OF VIROLOGY

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease

(2011) Stephen J. Nicholls et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Suppression of inflammation by a synthetic histone mimic

(2010) Edwige Nicodeme et al.   NATURE

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)

(2009) Nancy A. Thornberry et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM